Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. These new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years. The study reviews the current and future performance of the multiple sclerosis drug class market and covers major commercial opportunities and threats ...
<shortened url>
i guess ccsvi is a"threat"
Multiple Sclerosis Market Forecast
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1619 Views
-
Last post by frodo
-
- 0 Replies
- 1673 Views
-
Last post by frodo
-
- 1 Replies
- 1842 Views
-
Last post by frodo
-
- 0 Replies
- 1804 Views
-
Last post by frodo
-
- 0 Replies
- 3638 Views
-
Last post by frodo
-
- 0 Replies
- 2238 Views
-
Last post by frodo
-
- 0 Replies
- 1883 Views
-
Last post by NHE
-
- 0 Replies
- 1290 Views
-
Last post by frodo
-
- 0 Replies
- 1468 Views
-
Last post by frodo